1208077-18-2

Basic information

• Product Name: 2-Bromo-3,6-difluorophenol
• Synonyms: 2-Bromo-3,6-difluorophenol
• CAS NO: 1208077-18-2
• Molecular Formula: C₆H₃BrF₂O
• Molecular Weight: 208.9882264
• Mol File: 1208077-18-2.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 177.4±35.0 °C(Predicted)
• Appearance: /
• Density: 1.858±0.06 g/cm3(Predicted)
• PKA: 6.17±0.15(Predicted)
• CAS DataBase Reference: 2-Bromo-3,6-difluorophenol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3,6-difluorophenol(1208077-18-2)
• EPA Substance Registry System: 2-Bromo-3,6-difluorophenol(1208077-18-2)

Safety Data

• Hazardous Substances Data: 1208077-18-2(Hazardous Substances Data)

Upstream product

• 1208076-11-2 2-bromo-1,4-difluoro-3-methoxy-benzene 
• 2713-31-7 2,5-difluorophenol 

Downstream Products

• 1208076-11-2 2-bromo-1,4-difluoro-3-methoxy-benzene 

Relevant articles and documents

PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE

Described herein are phenoxy-pyridyl -pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

NOVEL COMPOUNDS, USES AND METHODS FOR THEIR PREPARATION

The present disclosure relates to novel compounds HIF-2α inhibitors and pharmaceutical compositions thereof which may be useful in the treatment and/or prevention of various conditions. The present disclosure also provides methods of preparing such HIF-2α inhibitors and compositions, and methods of using the same.

RADIOLABELLED mGluR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.